Literature DB >> 31848046

T618I CSF3R mutations in chronic neutrophilic leukemia induce oncogenic signals through aberrant trafficking and constitutive phosphorylation of the O-glycosylated receptor form.

Andrea Price1, Lawrence J Druhan1, Amanda Lance1, Gavin Clark2, C Greer Vestal1, Qing Zhang3, David Foureau4, Judy Parsons5, Alicia Hamilton5, Nury M Steuerwald5, Belinda R Avalos6.   

Abstract

Activating mutations in the membrane-proximal region of the colony-stimulating factor 3 receptor (CSF3R) are a hallmark of chronic neutrophilic leukemia (CNL) with the T618I mutation being most common. The mechanisms underlying constitutive activation of the T618I CSF3R and its signal propagation are poorly understood. Ligand-independent activation of the T618I CSF3R has previously been attributed to loss of receptor O-glycosylation and increased receptor dimerization. Here, we show that the T618I CSF3R is indeed glycosylated but undergoes enhanced spontaneous internalization and degradation that results in a marked decrease in its surface expression. Inhibition of the proteasome dramatically increases expression of the O-glycosylated T618I CSF3R. We also demonstrate that the O-glycosylated wild-type CSF3R is tyrosine phosphorylated in response to ligand but constitutively phosphorylated in cells expressing T618I CSF3R. Constitutive tyrosine phosphorylation of the O-glycosylated T618I receptor form correlated with activation of JAK2 and both the mutant receptor and JAK2 were found to be constitutively ubiquitinated. These observations provide novel insights into the mechanisms of oncogenic signaling by T618I CSF3R mutations in CNL.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Chronic neutrophilic leukemia; Glycosylation; Granulocyte-colony stimulating factor receptor; Ubiquitination

Mesh:

Substances:

Year:  2019        PMID: 31848046     DOI: 10.1016/j.bbrc.2019.12.030

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  6 in total

Review 1.  When Glycosylation Meets Blood Cells: A Glance of the Aberrant Glycosylation in Hematological Malignancies.

Authors:  Huining Su; Mimi Wang; Xingchen Pang; Feng Guan; Xiang Li; Ying Cheng
Journal:  Rev Physiol Biochem Pharmacol       Date:  2021       Impact factor: 5.545

2.  CSF3R T618I mutated chronic myelomonocytic leukemia: A proliferative subtype with a distinct mutational profile.

Authors:  Adelaide Kwon; Ibrahim Ibrahim; Tri Le; Jesse Manuel Jaso; Olga Weinberg; Franklin Fuda; Weina Chen
Journal:  Leuk Res Rep       Date:  2022-05-06

3.  Mutational Landscape of CEBPA in Mexican Pediatric Acute Myeloid Leukemia Patients: Prognostic Implications.

Authors:  Carolina Molina Garay; Karol Carrillo Sánchez; Luis Leonardo Flores Lagunes; Marco Jiménez Olivares; Anallely Muñoz Rivas; Beatríz Eugenia Villegas Torres; Hilario Flores Aguilar; Juan Carlos Núñez Enríquez; Elva Jiménez Hernández; Vilma Carolina Bekker Méndez; José Refugio Torres Nava; Janet Flores Lujano; Jorge Alfonso Martín Trejo; Minerva Mata Rocha; Aurora Medina Sansón; Laura Eugenia Espinoza Hernández; José Gabriel Peñaloza Gonzalez; Rosa Martha Espinosa Elizondo; Luz Victoria Flores Villegas; Raquel Amador Sanchez; María Luisa Pérez Saldívar; Omar Alejandro Sepúlveda Robles; Haydeé Rosas Vargas; Silvia Jiménez Morales; Patricia Galindo Delgado; Juan Manuel Mejía Aranguré; Carmen Alaez Verson
Journal:  Front Pediatr       Date:  2022-07-11       Impact factor: 3.569

4.  Comprehensive analysis of key genes and pathways for biological and clinical implications in thyroid-associated ophthalmopathy.

Authors:  Yueyue Wang; Yanfei Shao; Haitao Zhang; Jun Wang; Peng Zhang; Weizhong Zhang; Huanhuan Chen
Journal:  BMC Genomics       Date:  2022-09-02       Impact factor: 4.547

Review 5.  A review of granulocyte colony-stimulating factor receptor signaling and regulation with implications for cancer.

Authors:  Sungjin David Park; Apryl S Saunders; Megan A Reidy; Dawn E Bender; Shari Clifton; Katherine T Morris
Journal:  Front Oncol       Date:  2022-08-11       Impact factor: 5.738

6.  Heterozygous germ line CSF3R variants as risk alleles for development of hematologic malignancies.

Authors:  Amy M Trottier; Lawrence J Druhan; Ira L Kraft; Amanda Lance; Simone Feurstein; Maria Helgeson; Jeremy P Segal; Soma Das; Belinda R Avalos; Lucy A Godley
Journal:  Blood Adv       Date:  2020-10-27
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.